Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

NCT07647224 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07647224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
Lead sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
July 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants, multiple dose